Crossref
PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy
Clinical Ovarian Cancer · 2011
DOI: 10.1016/j.cloc.2012.02.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Ovarian Cancer, 2011. Verfasst von David Boruta und 2 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Boruta, D., Farley, J., & Birrer, M. J. (2011). PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy. Clinical Ovarian Cancer. https://doi.org/10.1016/j.cloc.2012.02.008
Vancouver
Boruta D, Farley J, Birrer MJ. PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy. Clinical Ovarian Cancer. 2011. doi:10.1016/j.cloc.2012.02.008
BibTeX
@article{Boruta2011,
author = {Boruta, David and Farley, John and Birrer, Michael J.},
title = {PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy},
journal = {Clinical Ovarian Cancer},
year = {2011},
doi = {10.1016/j.cloc.2012.02.008}
}
EUVIMED